• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

玻璃体黄斑牵引组自发消退的速率和时间:作为奥克纤溶酶治疗的替代方案,密切观察等待的作用是否应重新评估?

Rate and timing of spontaneous resolution in a vitreomacular traction group: should the role of watchful waiting be re-evaluated as an alternative to ocriplasmin therapy?

作者信息

Dimopoulos Spyridon, Bartz-Schmidt Karl-Ulrich, Gelisken Faik, Januschowski Kai, Ziemssen Focke

机构信息

Centre for Ophthalmology, Eberhard-Karls-University Tuebingen, Tuebingen, Germany.

出版信息

Br J Ophthalmol. 2015 Mar;99(3):350-3. doi: 10.1136/bjophthalmol-2014-304961. Epub 2014 Oct 23.

DOI:10.1136/bjophthalmol-2014-304961
PMID:25342274
Abstract

INTRODUCTION

The incidence of spontaneous resolution of vitreomacular traction (VMT) is low in studies of Ocriplasmin that have had a limited follow-up. Previous studies did not look for morphological parameters in the natural history using spectral-domain ocular coherence tomography (SD-OCT) imaging. The purpose of this study was to investigate how often and when spontaneous VMT resolution occurs in candidates for Ocriplasmin therapy.

METHODS

The study is a retrospective chart review of patients who would have high chances of a benefit by an Ocriplasmin injection, without epiretinal membrane or vitreomacular adhesion of 1500 µm or more on SD-OCT. Main outcome measures were the frequency of complete VMT resolution and the best corrected visual acuity seen in the natural history.

RESULTS

Out of the 46 patients that were included after screening 889 SD-OCT images, 20 were found to exhibit spontaneous resolution during the follow-up period (median: 594 days, 95% CI 567 to 719 days), the majority after 6-12 months of observation (95% CI 266 to 617 days). The group with spontaneous VMT resolution and a mean improvement of one line in best corrected visual acuity included a few patients losing vision by macular hole formation. In the absence of resolution, patients lost on average one early treatment diabetic retinopathy study letter per year. Younger age was found to increase the chance of spontaneous resolution.

CONCLUSIONS

A shorter follow-up might underestimate the incidence of spontaneous VMT resolution as the functional outcome of watchful waiting. The likelihood of resolution does not seem to decrease after 12 months.

摘要

引言

在玻璃体内注射ocriplasmin且随访有限的研究中,玻璃体黄斑牵引(VMT)自然消退的发生率较低。既往研究未使用频域光学相干断层扫描(SD - OCT)成像来探寻自然病程中的形态学参数。本研究的目的是调查在ocriplasmin治疗候选者中VMT自然消退的频率及发生时间。

方法

本研究是一项回顾性病历审查,针对那些接受ocriplasmin注射可能获益且SD - OCT显示无视网膜前膜或玻璃体黄斑粘连达1500 µm或以上的患者。主要观察指标为VMT完全消退的频率以及自然病程中最佳矫正视力情况。

结果

在筛查889张SD - OCT图像后纳入的46例患者中,20例在随访期间出现自然消退(中位数:594天,95%可信区间567至719天),大多数在观察6 - 12个月后出现(95%可信区间266至617天)。VMT自然消退且最佳矫正视力平均提高一行的组中,有少数患者因黄斑裂孔形成而视力下降。在未出现消退的患者中,每年平均丧失1个早期糖尿病视网膜病变研究视力表字母。发现年龄较小会增加自然消退的几率。

结论

作为密切观察等待的功能结果,较短的随访可能会低估VMT自然消退的发生率。12个月后消退的可能性似乎并未降低。

相似文献

1
Rate and timing of spontaneous resolution in a vitreomacular traction group: should the role of watchful waiting be re-evaluated as an alternative to ocriplasmin therapy?玻璃体黄斑牵引组自发消退的速率和时间:作为奥克纤溶酶治疗的替代方案,密切观察等待的作用是否应重新评估?
Br J Ophthalmol. 2015 Mar;99(3):350-3. doi: 10.1136/bjophthalmol-2014-304961. Epub 2014 Oct 23.
2
Real-life experience after intravitreal ocriplasmin for vitreomacular traction and macular hole: a spectral-domain optical coherence tomography prospective study.玻璃体内注射奥克纤溶酶治疗玻璃体黄斑牵引和黄斑裂孔的真实生活经验:一项频域光学相干断层扫描前瞻性研究。
Graefes Arch Clin Exp Ophthalmol. 2016 Feb;254(2):223-33. doi: 10.1007/s00417-015-3031-1. Epub 2015 May 5.
3
Outer retina reflectivity changes on sd-oct after intravitreal ocriplasmin for vitreomacular traction and macular hole.玻璃体内注射奥克纤溶酶治疗玻璃体黄斑牵拉和黄斑裂孔后,光谱域光学相干断层扫描(SD-OCT)显示的视网膜外层反射率变化
Retina. 2015 Jun;35(6):1144-50. doi: 10.1097/IAE.0000000000000544.
4
ANATOMICAL AND FUNCTIONAL OUTCOMES OF SYMPTOMATIC IDIOPATHIC VITREOMACULAR TRACTION: A Natural History Study From the Pan American Collaborative Retina Study Group.症状性特发性玻璃体黄斑牵拉的解剖学和功能转归:泛美视网膜协作研究组的一项自然史研究
Retina. 2016 Oct;36(10):1913-8. doi: 10.1097/IAE.0000000000001015.
5
Functional improvement assessed by multifocal electroretinogram after Ocriplasmin treatment for vitreomacular traction.玻璃体内注射纤溶酶治疗玻璃体黄斑牵拉后通过多焦视网膜电图评估的功能改善
BMC Ophthalmol. 2016 Jul 18;16:110. doi: 10.1186/s12886-016-0284-3.
6
Calculating the individual probability of successful ocriplasmin treatment in eyes with VMT syndrome: a multivariable prediction model from the EXPORT study.计算 VMT 综合征眼中 ocriplasmin 治疗成功的个体概率:来自 EXPORT 研究的多变量预测模型。
Br J Ophthalmol. 2018 Aug;102(8):1092-1097. doi: 10.1136/bjophthalmol-2017-310874. Epub 2017 Oct 31.
7
Improvement in Patient-Reported Visual Function After Ocriplasmin for Vitreomacular Adhesion: Results of the Microplasmin for Intravitreous Injection-Traction Release Without Surgical Treatment (MIVI-TRUST) Trials.玻璃体内注射奥克纤溶酶治疗玻璃体黄斑粘连后患者报告的视觉功能改善:非手术治疗的玻璃体内注射微纤溶酶-牵引松解(MIVI-TRUST)试验结果
JAMA Ophthalmol. 2015 Sep;133(9):997-1004. doi: 10.1001/jamaophthalmol.2015.1746.
8
Knowledge of vitreomacular traction (VMT) scenarios: Is doing nothing still a beneficial alternative and, if so, when?玻璃体黄斑牵拉(VMT)情况的相关知识:不作为仍是一种有益的选择吗?如果是,何时如此?
Graefes Arch Clin Exp Ophthalmol. 2016 Apr;254(4):615-6. doi: 10.1007/s00417-016-3301-6. Epub 2016 Feb 18.
9
Anatomical and visual outcomes following ocriplasmin treatment for symptomatic vitreomacular traction syndrome.ocriplasmin 治疗症状性玻璃体黄斑牵引综合征的解剖和视觉结果。
Br J Ophthalmol. 2014 Mar;98(3):356-60. doi: 10.1136/bjophthalmol-2013-304219. Epub 2013 Dec 19.
10
[Initial Clinical Experiences Using Ocriplasmin for the Treatment of Vitreomacular Traction with or without a Macular Hole].[使用奥克纤溶酶治疗伴有或不伴有黄斑裂孔的玻璃体黄斑牵引的初步临床经验]
Klin Monbl Augenheilkd. 2018 Jan;235(1):73-80. doi: 10.1055/s-0042-124511. Epub 2017 Mar 10.

引用本文的文献

1
Resolution of Vitreomacular Traction Following a Commercial Flight Simulator Experience.一次商业飞行模拟体验后玻璃体黄斑牵引的消退
J Vitreoretin Dis. 2025 Aug 22:24741264251366407. doi: 10.1177/24741264251366407.
2
[Vitreomacular traction: diagnostics, natural course, treatment decision and guideline recommendations].[玻璃体黄斑牵拉:诊断、自然病程、治疗决策及指南推荐]
Ophthalmologie. 2024 Jun;121(6):470-475. doi: 10.1007/s00347-024-02042-4. Epub 2024 May 29.
3
Calculating the individual probability of successful ocriplasmin treatment in eyes with vitreomacular traction-Validation and refinement of a multivariable prediction model.
计算玻璃体内黄斑牵引眼中 ocriplasmin 治疗成功的个体概率-多变量预测模型的验证和改进。
PLoS One. 2022 Jul 25;17(7):e0270120. doi: 10.1371/journal.pone.0270120. eCollection 2022.
4
Effect of pneumatic vitreolysis in management of patients with symptomatic focal vitreomacular traction.气体性玻璃体溶解术治疗有症状的局限性玻璃体黄斑牵引患者的疗效
Int J Retina Vitreous. 2022 Mar 28;8(1):22. doi: 10.1186/s40942-022-00376-2.
5
Pneumatic Vitreolysis with Perfluoropropane for Vitreomacular Traction with and without Macular Hole: DRCR Retina Network Protocols AG and AH.伴或不伴黄斑裂孔的玻璃体黄斑牵引的全氟化丙烷玻璃体气融术:DRCR 视网膜网络协议 AG 和 AH。
Ophthalmology. 2021 Nov;128(11):1592-1603. doi: 10.1016/j.ophtha.2021.05.005. Epub 2021 May 12.
6
Focal vitreomacular traction: Resolution after ocular massage.局限性玻璃体黄斑牵引:眼部按摩后缓解
Am J Ophthalmol Case Rep. 2019 Feb 22;14:61-63. doi: 10.1016/j.ajoc.2019.02.006. eCollection 2019 Jun.
7
Incidence and prevalence of vitreomacular traction with and without macular hole in Germany.德国伴有和不伴有黄斑裂孔的玻璃体黄斑牵引的发病率和患病率。
Clin Ophthalmol. 2019 Jan 15;13:177-188. doi: 10.2147/OPTH.S188704. eCollection 2019.
8
Comparison of the horizontal diameter to a modeled area of traction in eyes with vitreomacular traction: is the diameter close enough to the truth?玻璃体黄斑牵拉患者眼中水平径与模拟牵拉区域面积的比较:该直径与实际情况足够接近吗?
Graefes Arch Clin Exp Ophthalmol. 2018 Oct;256(10):1817-1822. doi: 10.1007/s00417-018-4055-0. Epub 2018 Jun 28.
9
[Unclear loss of vision following Descemet membrane endothelial keratoplasty].[Descemet膜内皮角膜移植术后不明原因的视力丧失]
Ophthalmologe. 2019 Jan;116(1):63-66. doi: 10.1007/s00347-018-0666-4.
10
Pneumatic Vitreolysis for Management of Symptomatic Focal Vitreomacular Traction.用于治疗症状性局限性玻璃体黄斑牵引的气体性玻璃体溶解术
J Ophthalmic Vis Res. 2017 Oct-Dec;12(4):419-423. doi: 10.4103/jovr.jovr_146_17.